Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Antares Pharma (ATRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 500,860
  • Shares Outstanding, K 160,532
  • Annual Sales, $ 63,550 K
  • Annual Income, $ -6,520 K
  • 60-Month Beta 1.15
  • Price/Sales 8.36
  • Price/Cash Flow N/A
  • Price/Book 13.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.03
  • Number of Estimates 5
  • High Estimate 0.01
  • Low Estimate -0.06
  • Prior Year -0.04
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.11 +0.32%
on 03/22/19
3.96 -21.21%
on 03/04/19
-0.10 (-3.11%)
since 02/22/19
3-Month
2.53 +23.32%
on 12/28/18
3.96 -21.21%
on 03/04/19
+0.43 (+15.99%)
since 12/21/18
52-Week
1.99 +56.78%
on 04/03/18
3.96 -21.21%
on 03/04/19
+0.88 (+39.29%)
since 03/22/18

Most Recent Stories

More News
AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study

Shares of AMAG (AMAG) decline almost 17% after the company's pregnancy drug, Makena fails in the post approval PROLONG study.

CELG : 88.15 (-1.65%)
BDSI : 5.11 (-3.58%)
ATRS : 3.12 (-5.74%)
AMAG : 12.16 (-4.33%)
Antares Pharma to Present at the Cowen and Company 39th Annual Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Cowen and Company 39 Annual Healthcare Conference on Wednesday March...

ATRS : 3.12 (-5.74%)
Antares Pharma Appoints Dr. Karen Smith to Board of Directors and Announces Retirement of Dr. Jacques Gonella

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Dr. Karen Smith to the Company's Board of Directors, filling the seat being vacated by the retirement of Dr. Jacques Gonella. Dr....

ATRS : 3.12 (-5.74%)
Antares Pharma Reports Fourth Quarter and Full Year 2018 Operating and Financial Results

Record Annual Revenue of $63.6 Million, a 17% Increase Over 2017 Revenue

BDSI : 5.11 (-3.58%)
ATRS : 3.12 (-5.74%)
CERC : 5.59 (-5.57%)
Antares Pharma to Present at the Raymond James & Associates 40th Annual Institutional Investors Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Raymond James & Associates 40 Annual Institutional Investors Conference...

ATRS : 3.12 (-5.74%)
Antares Pharma to Report Fourth Quarter and Full Year 2018 Financial and Operating Results

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its fourth quarter and full year 2018 financial results and recent operating progress before the market opens on Thursday, February 28,...

ATRS : 3.12 (-5.74%)
Hercules Capital Announces Multiple Outstanding Achievements by Numerous Investment Portfolio Companies

Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture growth stage companies backed by some...

ACRX : 3.16 (-2.77%)
AXON : 1.22 (-5.43%)
HTGC : 12.30 (-1.28%)
ATRS : 3.12 (-5.74%)
PRTK : 5.77 (-8.12%)
HCXZ : 24.56 (+0.24%)
HCXY : 24.85 (unch)
VSTM : 3.24 (-6.90%)
WMT : 98.28 (-0.79%)
Antares Pharma Announces the Appointment of Peter S. Greenleaf to Company's Board of Directors

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Peter S. Greenleaf to the Company's Board of Directors. Mr. Greenleaf has over 20 years of biopharmaceutical experience, and currently...

BDSI : 5.11 (-3.58%)
ATRS : 3.12 (-5.74%)
CERC : 5.59 (-5.57%)
Factors of Influence in 2018, Key Indicators and Opportunity within Antares Pharma, Encana, PPG Industries, Cato, Cimarex Energy, and Ormat Technologies -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Antares Pharma, Inc. (NASDAQ:ATRS),...

ECA : 7.02 (-4.88%)
PPG : 106.69 (-5.28%)
CATO : 14.08 (+0.43%)
XEC : 67.90 (-6.25%)
ATRS : 3.12 (-5.74%)
ORA : 54.65 (-0.78%)
Antares Pharma Announces the Commercial Availability of XYOSTED(TM) (Testosterone Enanthate) Injection -- A New Treatment for Adult Men Diagnosed With Testosterone Deficiency

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the availability of XYOSTED(TM) (testosterone enanthate) injection. XYOSTED(TM) is the only FDA approved subcutaneous testosterone product for once-weekly,...

ATRS : 3.12 (-5.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ATRS with:

Business Summary

Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes...

See More

Key Turning Points

2nd Resistance Point 3.42
1st Resistance Point 3.27
Last Price 3.12
1st Support Level 3.04
2nd Support Level 2.96

See More

52-Week High 3.96
Fibonacci 61.8% 3.21
Last Price 3.12
Fibonacci 50% 2.97
Fibonacci 38.2% 2.74
52-Week Low 1.99

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar